| P50 | author | Anja Seubert | Q40180981 |
| P2093 | author name string | Dan M Granoff | |
| | Oliver Koeberling | |
| | Serena Giuntini | |
| P2860 | cites work | Outer membrane protein vesicle vaccines for meningococcal disease | Q47770532 |
| | Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis | Q48761076 |
| | A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. | Q51910949 |
| | Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. | Q52019334 |
| | Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. | Q52032915 |
| | Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile | Q64131982 |
| | Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines | Q72173604 |
| | Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides | Q72283649 |
| | Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age | Q73318541 |
| | Stable shuttle vectors for Neisseria gonorrhoeae, Haemophilus spp. and other bacteria based on a single origin of replication | Q73480360 |
| | Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998 | Q74296031 |
| | Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease | Q80587615 |
| | Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: potential adjuvant for helminth vaccines? | Q80819707 |
| | Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent | Q81482651 |
| | The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease | Q81497539 |
| | Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks | Q82479800 |
| | Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870 | Q83294193 |
| | Functional significance of factor H binding to Neisseria meningitidis | Q83918204 |
| | Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling | Q28646159 |
| | Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein | Q30157650 |
| | CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription | Q33788408 |
| | Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry | Q34007332 |
| | Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity | Q34009161 |
| | Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model | Q34033214 |
| | Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains | Q34185172 |
| | Development of vaccines against meningococcal disease | Q34623334 |
| | Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease | Q34729067 |
| | Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. | Q35544353 |
| | A universal vaccine for serogroup B meningococcus | Q36101910 |
| | Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. | Q36313869 |
| | Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870 | Q36370598 |
| | Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine | Q36464572 |
| | The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance | Q36470692 |
| | Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870 | Q36638451 |
| | Multilocus sequence typing for global surveillance of meningococcal disease. | Q36683974 |
| | Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines | Q36710765 |
| | Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera | Q37075472 |
| | Vaccine potential of the Neisseria meningitidis 2086 lipoprotein | Q37115883 |
| | Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin | Q37126987 |
| | TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A | Q37292481 |
| | Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis | Q40090049 |
| | Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins | Q40105951 |
| | Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development | Q40513524 |
| | Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine | Q40564309 |
| | Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them | Q43633533 |
| | Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity | Q46121635 |
| | Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen | Q46348571 |
| | Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits | Q46620385 |
| P433 | issue | 2 | |
| P304 | page(s) | 156-162 | |
| P577 | publication date | 2008-12-24 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2 | |
| P478 | volume | 16 | |